Biotech Business - June 13, 2023
FDA confirm clinical benefit of BioArctic’s LEQEMBI
The FDA Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from the Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI 100 mg/mL intravenous injection for the treatment of Alzheimer’s disease. LEQEMBI received Accelerated approval from the FDA for the treatment of early Alzheimer’s disease on […]
Acquisition - June 12, 2023
Novartis to acquire Chinook Therapeutics for 3.2 billion USD upfront
Novartis has entered into an agreement to acquire Chinook Therapeutics, a Seattle, WA, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed deal, which is subject to customary closing conditions, is fully in line with Novartis strategy to focus on innovative medicines and will […]
Biotech Business - June 12, 2023
Novo Nordisk invests 15.9 billion DKK in expansion of manufacturing facilities
The company will invest 15.9 billion DKK starting in 2023 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases. The investment in Hillerød will create additional production capacity and increase Novo Nordisk’s ability to meet future market demands and be a key enabler for […]
Biotech Business - June 8, 2023
Mendus enters alliance with NorthX and announces a directed share issue
Mendus has entered into a manufacturing alliance with NorthX Biologics and has announced a directed share issue and a fully secured rights issue of units totaling approximately 317 million SEK in financing. In the alliance with NorthX, Mendus and NorthX will co-establish cell therapy manufacturing capabilities in Sweden, which will be used for late-stage development […]
Acquisition - June 6, 2023
Novo Nordisk offers 154 million EUR in negotiations to acquire Biocorp
Novo Nordisk has entered into exclusive negotiations for a controlling stake in Biocorp, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in the company at a price of 35 EUR per share in cash, representing a total equity value of approximately 154 million EUR. Biocorp is a French […]
Agreement - June 2, 2023
InDex Pharmaceuticals enters license agreement with Viatris Japan
InDex Pharmaceuticals has announced that a license agreement has been signed with Viatris Pharmaceutical Japan to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. “We are excited to start our collaboration with Viatris Japan with the common goal to register and commercialize cobitolimod for the Japanese market. Viatris Japan shares our […]
